Business Description
Terumo Corp
NAICS : 339113
ISIN : JP3546800008
Description
Terumo Corp manufactures and sells medical products and equipment. The firm has three main businesses: blood management, cardiac and vascular, and general hospital. The cardiac and vascular business generates the largest proportion of revenue and sells cardiac and endovascular interventional therapies, cardiovascular surgical systems, neurovascular products, and vascular graft products. The general hospital business includes diabetes management, consumer healthcare, drug and device technologies, and general hospital products. The blood management business sells blood component, therapeutic apheresis, and cellular technologies. Terumo generates the majority of its revenue in Asia, with Japan contributing the largest proportion of Asian revenue.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.78 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | 1.2 | |||||
| Interest Coverage | 36.48 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 5.89 | |||||
| Beneish M-Score | -2.43 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.6 | |||||
| 3-Year EBITDA Growth Rate | 5.3 | |||||
| 3-Year EPS without NRI Growth Rate | 1.8 | |||||
| 3-Year FCF Growth Rate | 10.4 | |||||
| 3-Year Book Growth Rate | 14.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 9.16 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.09 | |||||
| 9-Day RSI | 31.89 | |||||
| 14-Day RSI | 37.48 | |||||
| 6-1 Month Momentum % | 16.88 | |||||
| 12-1 Month Momentum % | -3.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.87 | |||||
| Quick Ratio | 1.06 | |||||
| Cash Ratio | 0.53 | |||||
| Days Inventory | 214.63 | |||||
| Days Sales Outstanding | 65.2 | |||||
| Days Payable | 75.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.96 | |||||
| Dividend Payout Ratio | 0.33 | |||||
| 3-Year Dividend Growth Rate | 12.6 | |||||
| Forward Dividend Yield % | 1.05 | |||||
| 5-Year Yield-on-Cost % | 1.25 | |||||
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | 1.12 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 50.77 | |||||
| Operating Margin % | 13.91 | |||||
| Net Margin % | 10.68 | |||||
| ROE % | 7.88 | |||||
| ROA % | 5.55 | |||||
| ROIC % | 6.81 | |||||
| ROC (Joel Greenblatt) % | 20.03 | |||||
| ROCE % | 8.63 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 33.97 | |||||
| Forward PE Ratio | 26.39 | |||||
| PE Ratio without NRI | 33.97 | |||||
| Shiller PE Ratio | 45.19 | |||||
| Price-to-Owner-Earnings | 55.83 | |||||
| PEG Ratio | 7.55 | |||||
| PS Ratio | 3.63 | |||||
| PB Ratio | 2.52 | |||||
| Price-to-Tangible-Book | 4.92 | |||||
| Price-to-Free-Cash-Flow | 101.59 | |||||
| Price-to-Operating-Cash-Flow | 28.83 | |||||
| EV-to-EBIT | 26.17 | |||||
| EV-to-Forward-EBIT | 19.35 | |||||
| EV-to-EBITDA | 16.36 | |||||
| EV-to-Forward-EBITDA | 14.92 | |||||
| EV-to-Revenue | 3.73 | |||||
| EV-to-Forward-Revenue | 3.43 | |||||
| EV-to-FCF | 110.82 | |||||
| Price-to-Projected-FCF | 2.31 | |||||
| Price-to-DCF (Earnings Based) | 2.11 | |||||
| Price-to-DCF (FCF Based) | 8.72 | |||||
| Price-to-Median-PS-Value | 0.97 | |||||
| Price-to-Peter-Lynch-Fair-Value | 5 | |||||
| Price-to-Graham-Number | 2.75 | |||||
| Price-to-Net-Current-Asset-Value | 18.59 | |||||
| Earnings Yield (Greenblatt) % | 3.81 | |||||
| Forward Rate of Return (Yacktman) % | 7.92 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Terumo Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 838,120 | ||
| EPS (TTM) (円) | 119.71 | ||
| Beta | 1.06 | ||
| Volatility % | 27.09 | ||
| 14-Day RSI | 37.48 | ||
| 14-Day ATR (円) | 93.22316 | ||
| 20-Day SMA (円) | 4306.8 | ||
| 12-1 Month Momentum % | -3.2 | ||
| 52-Week Range (円) | 3416 - 4772 | ||
| Shares Outstanding (Mil) | 744.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Terumo Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Terumo Corp Stock Events
| Event | Date | Price(円) | ||
|---|---|---|---|---|
| No Event Data | ||||
Terumo Corp Frequently Asked Questions
What is Terumo Corp(TSE:4543)'s stock price today?
The current price of TSE:4543 is 円4132.00. The 52 week high of TSE:4543 is 円4772.00 and 52 week low is 円3416.00.
When is next earnings date of Terumo Corp(TSE:4543)?
The next earnings date of Terumo Corp(TSE:4543) is .
Does Terumo Corp(TSE:4543) pay dividends? If so, how much?
The Dividend Yield %  of Terumo Corp(TSE:4543) is 0.96% (As of Today), Highest Dividend Payout Ratio of Terumo Corp(TSE:4543) was 0.39. The lowest was 0.21. And the median was 0.3. The  Forward Dividend Yield % of Terumo Corp(TSE:4543) is 1.05%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers